Rui Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rui Fu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Margaret L. Brandeau
Department of Management Science and Engineering, Stanford University, Stanford
2 shared publications- Alexander Gutfraind
The Program for Experimental & Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago
1 shared publication Clea C Sarnquist
Division of Pediatric Infectious Diseases, California
1 shared publicationDouglas K. Owens
VA Palo Alto Health Care System, Palo Alto
1 shared publicationJason R Andrews
Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, California
1 shared publicationJonathan Altamirano
Division of Pediatric Infectious Diseases, California
1 shared publication
Latest Publications
- Open Access
- 30 October 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 67 (suppl_1) , S26-S34
Assessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings
The Polio Eradication and Endgame Strategic Plan 2013–2018 calls for the gradual withdrawal of oral poliovirus vaccine (OPV) from routine immunization. We aimed to quantify the transmission potential of Sabin strains from OPV when it is reintroduced, accidentally or deliberately, in a community vaccinated with inactivated poliovirus vaccine alone. We built an individual-based stochastic epidemiological model that allows independent spread of 3 Sabin serotypes and differential transmission rates within versus between households. Model parameters were estimated by fitting to data from a prospective cohort in Mexico. We calculated the effective reproductive number for the Mexico cohort and simulated scenarios of Sabin strain resurgence under postcessation conditions, projecting the risk of prolonged circulation, which could lead to circulating vaccine-derived poliovirus (cVDPV). The estimated effective reproductive number for naturally infected individuals was about 1 for Sabin 2 and Sabin 3 (OPV2 and OPV3) in a postcessation setting. Most transmission events occurred between households. We estimated the probability of circulation for >9 months to be (1) <<1% for all 3 serotypes when 90% of children <5 years of age were vaccinated in a hypothetical outbreak control campaign; (2) 45% and 24% for Sabin 2 and Sabin 3, respectively, when vaccine coverage dropped to 10%; (3) 37% and 8% for Sabin 2 and Sabin 3, respectively, when a single active shedder appeared in a community. Critical factors determining the risk of cVDPV emergence are the scale at which OPV is reintroduced and the between-household transmission rate for poliovirus, with intermediate values posing the greatest risk.
- 30 October 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 67 (suppl_1) , S26-S34
Open AccessAssessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings
The Polio Eradication and Endgame Strategic Plan 2013–2018 calls for the gradual withdrawal of oral poliovirus vaccine (OPV) from routine immunization. We aimed to quantify the transmission potential of Sabin strains from OPV when it is reintroduced, accidentally or deliberately, in a community vaccinated with inactivated poliovirus vaccine alone. We built an individual-based stochastic epidemiological model that allows independent spread of 3 Sabin serotypes and differential transmission rates within versus between households. Model parameters were estimated by fitting to data from a prospective cohort in Mexico. We calculated the effective reproductive number for the Mexico cohort and simulated scenarios of Sabin strain resurgence under postcessation conditions, projecting the risk of prolonged circulation, which could lead to circulating vaccine-derived poliovirus (cVDPV). The estimated effective reproductive number for naturally infected individuals was about 1 for Sabin 2 and Sabin 3 (OPV2 and OPV3) in a postcessation setting. Most transmission events occurred between households. We estimated the probability of circulation for >9 months to be (1) <<1% for all 3 serotypes when 90% of children <5 years of age were vaccinated in a hypothetical outbreak control campaign; (2) 45% and 24% for Sabin 2 and Sabin 3, respectively, when vaccine coverage dropped to 10%; (3) 37% and 8% for Sabin 2 and Sabin 3, respectively, when a single active shedder appeared in a community. Critical factors determining the risk of cVDPV emergence are the scale at which OPV is reintroduced and the between-household transmission rate for poliovirus, with intermediate values posing the greatest risk.
- 13 March 2018
- Published by Wolters Kluwer Health in AIDS
- Vol. 32 (5) , 663-672
Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs
Background: Oral HIV preexposure prophylaxis (PrEP) has been recommended as a means of HIV prevention among people who inject drugs (PWIDs) but, at current prices, is unlikely to be cost-effective for all PWID. Objective: To determine the cost-effectiveness of alternative strategies for enrolling PWID in PrEP. Design: Dynamic network model that captures HIV transmission and progression among PWID in a representative US urban center. Outcome measures: HIV infections averted, discounted costs and quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Intervention: We assume 25% PrEP coverage and investigate four strategies: first, random PWID are enrolled (Unselected Enrollment); second, individuals are randomly selected and enrolled together with their partners (Enroll Partners); third, individuals with the highest number of sexual and needle-sharing partnerships are enrolled (Most Partners); fourth, individuals with the greatest number of infected partners are enrolled (Most Positive Partners). Results: PrEP can achieve significant health benefits: compared with the status quo of no PrEP, the strategies gain 1114 QALYs (Unselected Enrollment), 2194 QALYs (Enroll Partners), 2481 QALYs (Most Partners), and 3046 QALYs (Most Positive Partners) over 20 years in a population of approximately 8500 people. The incremental cost-effectiveness ratio of each strategy compared with the status quo (cost per QALY gained) is $272 000 (Unselected Enrollment), $158 000 (Enroll Partners), $124 000 (Most Partners), and $101 000 (Most Positive Partners). All strategies except Unselected Enrollment are cost-effective according to WHO criteria. Conclusion: Selection of high-risk PWID for PrEP can improve the cost-effectiveness of PrEP for PWID.
- 13 March 2018
- Published by Wolters Kluwer Health in AIDS
- Vol. 32 (5) , 663-672
Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs
Background: Oral HIV preexposure prophylaxis (PrEP) has been recommended as a means of HIV prevention among people who inject drugs (PWIDs) but, at current prices, is unlikely to be cost-effective for all PWID. Objective: To determine the cost-effectiveness of alternative strategies for enrolling PWID in PrEP. Design: Dynamic network model that captures HIV transmission and progression among PWID in a representative US urban center. Outcome measures: HIV infections averted, discounted costs and quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Intervention: We assume 25% PrEP coverage and investigate four strategies: first, random PWID are enrolled (Unselected Enrollment); second, individuals are randomly selected and enrolled together with their partners (Enroll Partners); third, individuals with the highest number of sexual and needle-sharing partnerships are enrolled (Most Partners); fourth, individuals with the greatest number of infected partners are enrolled (Most Positive Partners). Results: PrEP can achieve significant health benefits: compared with the status quo of no PrEP, the strategies gain 1114 QALYs (Unselected Enrollment), 2194 QALYs (Enroll Partners), 2481 QALYs (Most Partners), and 3046 QALYs (Most Positive Partners) over 20 years in a population of approximately 8500 people. The incremental cost-effectiveness ratio of each strategy compared with the status quo (cost per QALY gained) is $272 000 (Unselected Enrollment), $158 000 (Enroll Partners), $124 000 (Most Partners), and $101 000 (Most Positive Partners). All strategies except Unselected Enrollment are cost-effective according to WHO criteria. Conclusion: Selection of high-risk PWID for PrEP can improve the cost-effectiveness of PrEP for PWID.
- 1 March 2016
- Published by Elsevier in Mathematical Biosciences
- Vol. 273, 102-113
Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections
- 1 March 2016
- Published by Elsevier in Mathematical Biosciences
- Vol. 273, 102-113
Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections